Table 4 Weight dose deposited according to MRONJ Clinical Stage and Treatment Response
From: Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
| Â | Estimates (SE) | 95% | CI | Significance |
|---|---|---|---|---|
Weight dose deposited according to MRONJ Clinical Stage | ||||
 Ln [weighted dose] | 1.113 (0.247) | 0.63 | 1.60 | < 0.001 |
 Age | − 0.043 (0.030) | − 0.10 | 0.02 | > 0.05 |
 Sex | − 1.033 (1.168) | − 3.32 | 1.23 | > 0.05 |
 MRONJ site | 1.635 (1.344) | − 1.00 | 4.27 | > 0.05 |
 Medical comorbidity | 0.089 (0.539) | − 0.97 | 1.15 | > 0.05 |
 ONJ stage | 5.921 (2.898) | 0.24 | 11.60 | < 0.05 |
Weight dose deposited according to treatment response | ||||
 Ln [weighted dose] | 0.443 (0.160) | 0.13 | 0.76 | < 0.05 |
 Age | 0.012 (0.023) | − 0.03 | 0.06 | > 0.05 |
 Sex | 0.237 (0.918) | − 1.56 | 2.04 | > 0.05 |
 MRONJ site | − 0.917 (1.135) | − 3.14 | 1.31 | > 0.05 |
 Medical comorbidity | 0.476 (0.440) | − 0.39 | 1.34 | > 0.05 |
 Tx. response | 4.757 (2.354) | 0.14 | 9.37 | < 0.05 |